Mayo Clinic Talks Rx for Weight Loss: A Closer Look Series “Who is a Candidate for a GLP-1 Medication?”
7 snips
Jan 8, 2026 In this engaging discussion, endocrinologist Dr. Meera Shah and obesity medicine expert Dr. Tamim I. Rajjo delve into the promising world of GLP-1 medications for weight loss. They cover the history and FDA approval milestones of these drugs, as well as their physiological impacts on appetite and caloric intake. The guests thoughtfully discuss who qualifies for GLP-1 therapy, the importance of tailoring treatments based on individual health factors, and potential side effects to watch out for, providing valuable insights for anyone interested in obesity management.
AI Snips
Chapters
Transcript
Episode notes
GLP-1s Have A Long, Revealing History
- GLP-1 receptor agonists were identified over 40 years ago and first FDA-approved for diabetes in 2005.
- Their glucose-lowering use revealed weight loss as a consistent, clinically useful effect.
Brain-Gut Pathway Drives Weight Loss
- GLP-1s act on the brain-gut axis to increase satiety and slow gastric emptying.
- They also reduce reward-driven cravings, substantially lowering caloric intake.
Benefits Require Ongoing Treatment
- GLP-1 effects persist only while the medication is active and reverse after stopping.
- Weight regain after discontinuation is common, making long-term use a key consideration.